76 related articles for article (PubMed ID: 25828577)
1. Repurposing de novo designed entities reveals phosphodiesterase 3B and cathepsin L modulators.
Rodrigues T; Lin YC; Hartenfeller M; Renner S; Lim YF; Schneider G
Chem Commun (Camb); 2015 May; 51(35):7478-81. PubMed ID: 25828577
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks.
Song J; Jones LM; Chavarria GE; Charlton-Sevcik AK; Jantz A; Johansen A; Bayeh L; Soeung V; Snyder LK; Lade SD; Chaplin DJ; Trawick ML; Pinney KG
Bioorg Med Chem Lett; 2013 May; 23(9):2801-7. PubMed ID: 23540644
[TBL] [Abstract][Full Text] [Related]
3. The synthesis and biological evaluation of nucleobases/tetrazole hybrid compounds: A new class of phosphodiesterase type 3 (PDE3) inhibitors.
Shekouhy M; Karimian S; Moaddeli A; Faghih Z; Delshad Y; Khalafi-Nezhad A
Bioorg Med Chem; 2020 Jun; 28(12):115540. PubMed ID: 32503691
[TBL] [Abstract][Full Text] [Related]
4. Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.
Duan LM; Yu HY; Li YL; Jia CJ
Bioorg Med Chem; 2015 Sep; 23(18):6111-7. PubMed ID: 26319621
[TBL] [Abstract][Full Text] [Related]
5. Modulating the cyclic guanosine monophosphate substrate selectivity of the phosphodiesterase 3 inhibitors by pyridine, pyrido[2,3-d]pyrimidine derivatives and their effects upon the growth of HT-29 cancer cell line.
Abadi AH; Hany MS; Elsharif SA; Eissa AA; Gary BD; Tinsley HN; Piazza GA
Chem Pharm Bull (Tokyo); 2013; 61(4):405-10. PubMed ID: 23546000
[TBL] [Abstract][Full Text] [Related]
6. Azepanone-based inhibitors of human cathepsin S: optimization of selectivity via the P2 substituent.
Kerns JK; Nie H; Bondinell W; Widdowson KL; Yamashita DS; Rahman A; Podolin PL; Carpenter DC; Jin Q; Riflade B; Dong X; Nevins N; Keller PM; Mitchell L; Tomaszek T
Bioorg Med Chem Lett; 2011 Aug; 21(15):4409-15. PubMed ID: 21733692
[TBL] [Abstract][Full Text] [Related]
7. New 2-(2-Phenylethyl)chromone Derivatives and Inhibitors of Phosphodiesterase (PDE) 3A from Agarwood.
Sugiyama T; Narukawa Y; Shibata S; Masui R; Kiuchia F
Nat Prod Commun; 2016 Jun; 11(6):795-7. PubMed ID: 27534119
[TBL] [Abstract][Full Text] [Related]
8. Novel peptidyl aryl vinyl sulfones as highly potent and selective inhibitors of cathepsins L and B.
Mendieta L; Picó A; Tarragó T; Teixidó M; Castillo M; Rafecas L; Moyano A; Giralt E
ChemMedChem; 2010 Sep; 5(9):1556-67. PubMed ID: 20652927
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration.
Ochiai K; Takita S; Kojima A; Eiraku T; Iwase K; Kishi T; Ohinata A; Yageta Y; Yasue T; Adams DR; Kohno Y
Bioorg Med Chem Lett; 2013 Jan; 23(1):375-81. PubMed ID: 23200255
[TBL] [Abstract][Full Text] [Related]
10. Optimization of dipeptidic inhibitors of cathepsin L for improved Toxoplasma gondii selectivity and CNS permeability.
Zwicker JD; Diaz NA; Guerra AJ; Kirchhoff PD; Wen B; Sun D; Carruthers VB; Larsen SD
Bioorg Med Chem Lett; 2018 Jun; 28(10):1972-1980. PubMed ID: 29650289
[TBL] [Abstract][Full Text] [Related]
11. Identification of new peptide amides as selective cathepsin L inhibitors: the first step towards selective irreversible inhibitors?
Torkar A; Lenarčič B; Lah T; Dive V; Devel L
Bioorg Med Chem Lett; 2013 May; 23(10):2968-73. PubMed ID: 23562595
[TBL] [Abstract][Full Text] [Related]
12. Microarray-guided discovery of two-photon (2P) small molecule probes for live-cell imaging of cysteinyl cathepsin activities.
Na Z; Li L; Uttamchandani M; Yao SQ
Chem Commun (Camb); 2012 Jul; 48(58):7304-6. PubMed ID: 22711056
[TBL] [Abstract][Full Text] [Related]
13. Numerous distinct PKA-, or EPAC-based, signalling complexes allow selective phosphodiesterase 3 and phosphodiesterase 4 coordination of cell adhesion.
Raymond DR; Wilson LS; Carter RL; Maurice DH
Cell Signal; 2007 Dec; 19(12):2507-18. PubMed ID: 17884339
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity.
Ochiai K; Ando N; Iwase K; Kishi T; Fukuchi K; Ohinata A; Zushi H; Yasue T; Adams DR; Kohno Y
Bioorg Med Chem Lett; 2011 Sep; 21(18):5451-6. PubMed ID: 21764304
[TBL] [Abstract][Full Text] [Related]
15. A combined crystallographic and molecular dynamics study of cathepsin L retrobinding inhibitors.
Shenoy RT; Chowdhury SF; Kumar S; Joseph L; Purisima EO; Sivaraman J
J Med Chem; 2009 Oct; 52(20):6335-46. PubMed ID: 19761244
[TBL] [Abstract][Full Text] [Related]
16. Some thiocarbamoyl based novel anticathepsin agents.
Kaur R; Raghav N
Bioorg Chem; 2020 Nov; 104():104174. PubMed ID: 32932119
[TBL] [Abstract][Full Text] [Related]
17. Design and Development of Novel 4-(4-(1H-Tetrazol-5-yl)-1H-pyrazol-1-yl)-6-morpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine as Cardiotonic Agent via Inhibition of PDE3.
Mao ZW; Li QL; Wang P; Sun YL; Liu Y
Arch Pharm (Weinheim); 2016 Apr; 349(4):268-76. PubMed ID: 26934198
[TBL] [Abstract][Full Text] [Related]
18. SAR studies of differently functionalized chalcones based hydrazones and their cyclized derivatives as inhibitors of mammalian cathepsin B and cathepsin H.
Raghav N; Singh M
Bioorg Med Chem; 2014 Aug; 22(15):4233-45. PubMed ID: 24913985
[TBL] [Abstract][Full Text] [Related]
19. Chalcones, inhibitors for topoisomerase I and cathepsin B and L, as potential anti-cancer agents.
Kim SH; Lee E; Baek KH; Kwon HB; Woo H; Lee ES; Kwon Y; Na Y
Bioorg Med Chem Lett; 2013 Jun; 23(11):3320-4. PubMed ID: 23608763
[TBL] [Abstract][Full Text] [Related]
20. Cyclic nucleotide phosphodiesterase 3 signaling complexes.
Ahmad F; Degerman E; Manganiello VC
Horm Metab Res; 2012 Sep; 44(10):776-85. PubMed ID: 22692928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
